Needham Reiterates Hold on Sage Therapeutics
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Ami Fadia has reiterated a Hold rating on Sage Therapeutics (NASDAQ:SAGE).

June 11, 2024 | 12:40 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Needham analyst Ami Fadia has reiterated a Hold rating on Sage Therapeutics. This suggests a neutral stance on the stock, indicating that the analyst does not see significant upside or downside in the near term.
The reiteration of a Hold rating by Needham suggests that the analyst does not expect significant movement in the stock price in the short term. This neutral stance indicates that investors might not see substantial gains or losses based on this rating alone.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100